Stockscreener 앱 받기
67.90
0.87%
-0.41
전일 마감가:
$68.31
열려 있는:
$67.86
하루 거래량:
715.01K
Relative Volume:
0.59
시가총액:
$5.39B
수익:
$900.66M
순이익/손실:
$-453.20M
주가수익비율:
-11.43
EPS:
-5.94
순현금흐름:
$-274.19M
1주 성능:
+0.95%
1개월 성능:
+3.59%
6개월 성능:
+35.57%
1년 성능:
+67.32%
1일 변동 폭
$66.10
$69.23
1주일 범위
$66.00
$69.88
52주 변동 폭
$35.95
$69.88
PTC 테라퓨틱스 Stock (PTCT) Company Profile
명칭
Ptc Therapeutics Inc
전화
(908) 222-7000
주소
500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
PTCT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PTCT
Ptc Therapeutics Inc
|
67.89 | 5.43B | 900.66M | -453.20M | -274.19M | -5.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.85 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.00 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
430.90 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
825.21 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.15 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
PTC 테라퓨틱스 Stock (PTCT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-20 | 개시 | Wells Fargo | Overweight |
| 2025-06-17 | 개시 | Truist | Buy |
| 2025-05-09 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-05-07 | 업그레이드 | Citigroup | Sell → Neutral |
| 2025-03-11 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2025-03-07 | 개시 | Scotiabank | Sector Perform |
| 2024-12-13 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-03 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-10-10 | 재개 | Raymond James | Mkt Perform |
| 2024-09-04 | 개시 | Robert W. Baird | Outperform |
| 2024-08-26 | 재개 | UBS | Buy |
| 2024-05-20 | 업그레이드 | Raymond James | Underperform → Mkt Perform |
| 2023-12-19 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2023-12-08 | 개시 | Wells Fargo | Overweight |
| 2023-10-30 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2023-10-27 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2023-10-06 | 다운그레이드 | Truist | Buy → Hold |
| 2023-09-18 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2023-09-15 | 다운그레이드 | Raymond James | Outperform → Underperform |
| 2023-03-17 | 개시 | SVB Securities | Market Perform |
| 2022-12-14 | 개시 | Goldman | Sell |
| 2022-09-12 | 개시 | Jefferies | Buy |
| 2022-09-09 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-09-01 | 개시 | Citigroup | Buy |
| 2022-04-04 | 재개 | Cantor Fitzgerald | Overweight |
| 2021-10-18 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2021-04-26 | 재개 | Credit Suisse | Neutral |
| 2021-03-29 | 업그레이드 | RBC Capital Mkts | Underperform → Sector Perform |
| 2021-02-12 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-01-05 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-11-30 | 다운그레이드 | RBC Capital Mkts | Sector Perform → Underperform |
| 2020-10-30 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-10-28 | 개시 | UBS | Neutral |
| 2020-10-07 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2020-08-25 | 개시 | Raymond James | Outperform |
| 2020-04-09 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-02-20 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-02-20 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-11-12 | 개시 | SunTrust | Buy |
| 2019-05-13 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2019-04-11 | 개시 | Bernstein | Outperform |
| 2018-10-03 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
| 2018-10-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-07-19 | 개시 | Credit Suisse | Outperform |
| 2018-06-18 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-04-04 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2018-01-29 | 재개 | RBC Capital Mkts | Sector Perform |
| 2017-11-16 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2017-10-26 | 다운그레이드 | BofA/Merrill | Neutral → Underperform |
| 2017-10-09 | 다운그레이드 | JP Morgan | Neutral → Underweight |
모두보기
PTC 테라퓨틱스 주식(PTCT)의 최신 뉴스
Will PTC Therapeutics Inc. (BH3) stock deliver stable dividends2025 Winners & Losers & High Win Rate Trade Tips - newser.com
What To Expect From PTC Therapeutics Inc (PTCT) Q3 2025 Earnings - GuruFocus
How PTC Therapeutics Inc. stock compares to growth peersDividend Hike & Safe Capital Growth Plans - newser.com
Detecting support and resistance levels for PTC Therapeutics Inc.2025 Winners & Losers & Verified Swing Trading Watchlists - newser.com
How to read the order book for PTC Therapeutics Inc.Weekly Earnings Recap & Real-Time Market Sentiment Alerts - newser.com
Wolverine Asset Management LLC Trims Stake in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics, Inc. $PTCT Stake Lessened by Pinnacle Associates Ltd. - MarketBeat
How PTC Therapeutics Inc. stock benefits from global expansion2025 Volume Leaders & Verified Entry Point Signals - newser.com
PTC Therapeutics, Inc. $PTCT Shares Acquired by Y Intercept Hong Kong Ltd - MarketBeat
Can PTC Therapeutics Inc. stock reach $100 price targetWeekly Investment Summary & Fast Exit and Entry Trade Guides - newser.com
Is PTC Therapeutics Inc. stock a top pick in earnings season2025 Performance Recap & Advanced Swing Trade Entry Plans - newser.com
Brighton Jones LLC Invests $226,000 in PTC Therapeutics, Inc. $PTCT - MarketBeat
Published on: 2025-11-02 01:56:33 - newser.com
Is PTC Therapeutics Inc. (BH3) stock safe for risk averse investorsJuly 2025 Snapshot & Fast Moving Stock Watchlists - newser.com
PTC Therapeutics submits NDA for Friedreich ataxia treatment vatiquinone - MSN
PTC Therapeutics (NASDAQ:PTCT) Director Sells $1,088,787.00 in Stock - MarketBeat
PTC Therapeutics Hits New 52-Week High of $69.88, Up 81.1% - Markets Mojo
Why PTC Therapeutics Inc. (BH3) stock is trending on social media2025 Institutional Moves & Weekly Chart Analysis and Guides - newser.com
AlphaQuest LLC Raises Stake in PTC Therapeutics, Inc. $PTCT - MarketBeat
Published on: 2025-11-01 00:56:06 - newser.com
Insider Sell: Emma Reeve Sells 15,666 Shares of PTC Therapeutics Inc (PTCT) - GuruFocus
PTC Therapeutics Inc expected to post a loss of $1.37 a shareEarnings Preview - TradingView
Reeve Emma, director at Ptc Therapeutics, sells $1.08 million in shares - Investing.com Australia
Reeve Emma, director at Ptc Therapeutics, sells $1.08 million in shares By Investing.com - Investing.com South Africa
PTC Therapeutics (NASDAQ:PTCT) Hits New 12-Month HighWhat's Next? - MarketBeat
Ptc Therapeutics stock hits 52-week high at 69.53 USD By Investing.com - Investing.com Australia
How Investors May Respond To PTC Therapeutics (PTCT) Analysts' Optimism on Sephience Launch Momentum - Sahm
2025-10-31 | PTC Therapeutics to Participate at Upcoming Investor Conferences | NDAQ:PTCT | Press Release - Stockhouse
PTC Therapeutics Inc. stock prediction for this weekWeekly Trend Recap & Low Risk Entry Point Guides - newser.com
Will PTC Therapeutics Inc. (BH3) stock attract long term capital inflowsJuly 2025 Sector Moves & Community Consensus Trade Alerts - newser.com
PTC Therapeutics (NASDAQ:PTCT) NASDAQ Composite Leads Biotech - Kalkine Media
How to forecast PTC Therapeutics Inc. trends using time seriesWall Street Watch & Technical Entry and Exit Alerts - newser.com
Ptc Therapeutics stock hits 52-week high at 69.53 USD - Investing.com
How Recent Developments Are Shaping the PTC Therapeutics Investment Story - Yahoo Finance
PTC Therapeutics (PTCT) to Release Earnings on Tuesday - MarketBeat
Published on: 2025-10-29 06:46:31 - newser.com
PTC Therapeutics, Inc. $PTCT Shares Sold by Allianz Asset Management GmbH - MarketBeat
Sector ETF performance correlation with PTC Therapeutics Inc.July 2025 Patterns & Weekly High Momentum Picks - newser.com
Jefferies Maintains PTC Therapeutics (PTCT) Buy Recommendation - Nasdaq
Huntington’s Disease | Clinical Landscape, Key Companies, Therapeutic Assessment, Treatment Algorithms, and Pipeline Insights – featuring leading players such as Hoffmann-La Roche, PTC Therapeutics, A - Barchart.com
PD-1 and PD-L1 Inhibitors Clinical Landscape, Key Companies, Therapeutic Evaluation, Treatment Approaches, and Pipeline Insights | Hoffmann-La Roche, PTC Therapeutics, Annexon, Alnylam Pharmaceuticals - Barchart.com
Bevacizumab: Clinical Overview, Key Companies, Therapeutic Insights, Treatment Strategies, and Pipeline Analysis | Hoffmann-La Roche, PTC Therapeutics, Annexon, Alnylam Pharmaceuticals, Neuvivo, BPG B - Barchart.com
Published on: 2025-10-28 14:58:18 - fcp.pa.gov.br
Bank of America Securities Lifts PT on PTC Therapeutics (PTCT) to $87 From $76 - Insider Monkey
PTC 테라퓨틱스 (PTCT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.15%
1.65%
자본화:
|
볼륨(24시간):